Your Good Partner in Biology Research

  1. 首页
  2. 试剂盒
  3. 酶联免疫试剂盒
  4. Human Rho GDP-dissociation inhibitor 2(ARHGDIB) ELISA kit

Human Rho GDP-dissociation inhibitor 2(ARHGDIB) ELISA kit

  • 中文名称：
    人Rho GDP解离抑制因子2(ARHGDIB)酶联免疫试剂盒
  • 货号：
    CSB-EL002038HU
  • 规格：
    96T/48T
  • 价格：
    ￥3600/￥2500
  • 其他：

产品详情

  • 产品描述：

    This Human ARHGDIB ELISA Kit was designed for the quantitative measurement of Human ARHGDIB protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 25 pg/mL-1600 pg/mL and the sensitivity is 6.25 pg/mL.

  • 别名：
    Arhgdib ELISA Kit; D4 ELISA Kit; D4 GDP dissociation inhibitor ELISA Kit; GDIA 2 ELISA Kit; GDIA2 ELISA Kit; GDID 4 ELISA Kit; GDID4 ELISA Kit; GDIR2_HUMAN ELISA Kit; GDP dissociation inhibitor D4 ELISA Kit; LY GDI ELISA Kit; Ly-GDI ELISA Kit; LYGDI ELISA Kit; MGC108926 ELISA Kit; RAP1GN1 ELISA Kit; Rho GDI 2 ELISA Kit; Rho GDI beta ELISA Kit; Rho GDI2 ELISA Kit; Rho GDP dissociation inhibitor (GDI) beta ELISA Kit; Rho GDP dissociation inhibitor 2 ELISA Kit; Rho GDP dissociation inhibitor beta ELISA Kit; Rho GDP-dissociation inhibitor 2 ELISA Kit; Rho-GDI beta ELISA Kit; RhoGDI2 ELISA Kit
  • 缩写：
  • Uniprot No.：
  • 种属：
    Homo sapiens (Human)
  • 样本类型：
    serum, plasma, tissue homogenates, cell lysates
  • 检测范围：
    25 pg/mL-1600 pg/mL
  • 灵敏度：
    6.25 pg/mL
  • 反应时间：
    1-5h
  • 样本体积：
    50-100ul
  • 检测波长：
    450 nm
  • 研究领域：
    Signal Transduction
  • 测定原理：
    quantitative
  • 测定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%        
    Three samples of known concentration were tested twenty times on one plate to assess.    
    Inter-assay Precision (Precision between assays): CV%<10%        
    Three samples of known concentration were tested in twenty assays to assess.      
                   
  • 线性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human ARHGDIB in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
    　 Sample Serum(n=4)    
    1:1 Average % 87    
    Range % 85-93    
    1:2 Average % 104    
    Range % 96-108    
    1:4 Average % 92    
    Range % 85-96    
    1:8 Average % 101    
    Range % 98-105    
  • 回收率：
    The recovery of human ARHGDIB spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
     
    Sample Type Average % Recovery Range    
    Serum (n=5) 92 88-96    
    EDTA plasma (n=4) 103 98-107    
                   
                   
  • 标准曲线：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
     
    pg/ml OD1 OD2 Average Corrected    
    1600 2.921 2.844 2.883 2.711    
    800 2.334 2.241 2.288 2.116    
    400 1.534 1.491 1.513 1.341    
    200 0.887 0.867 0.877 0.705    
    100 0.596 0.581 0.589 0.417    
    50 0.370 0.362 0.366 0.194    
    25 0.238 0.234 0.236 0.064    
    0 0.173 0.171 0.172 　    
  • 数据处理：
  • 货期：
    3-5 working days

产品评价

靶点详情

  • 功能：
    Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them. Regulates reorganization of the actin cytoskeleton mediated by Rho family members.
  • 基因功能参考文献：
    1. RhoGDIbeta overexpression led to downregulation of miR-200c, whereas miR-200c was able directly to target 3'-UTR of jnk2mRNA and attenuated JNK2 protein translation, which resulted in attenuation of Sp1mRNA and protein expression in turn, inhibiting Sp1-dependent MMP-2 transcription. PMID: 28846829
    2. Binders to RhoGDI2 as a potential anti-cancer target have been first reported, and their weak interactions were depicted using NMR spectroscopy. PMID: 27721047
    3. Delta19RhoGDIbeta has an apoptosisindependent role in the phorbol 12myristate 13acetate induced differentiation of THP1 cells to macrophages. PMID: 28260067
    4. The caspase-3-cleaved RhoGDIbeta is a possible determinant to promote cancer spreading. PMID: 26919575
    5. Our interpretation of these contradictions is that truncation and/or mutation of RhoGDI2 perturbs its conformation to expose a site that adventitiously binds FLNA and is not a bona-fide interaction. PMID: 26707877
    6. Results show that RhoGDI2 suppresses bladder cancer metastatic colonization via negative regulation of RhoC activity, providing a rationale for the development of therapeutics that target RhoC signaling. PMID: 25516960
    7. These findings indicate that RhoGDI2 repressed the activity of Rac1 and may be involved in the rearrangement of cytoskeleton in lung cancer cells. PMID: 25562149
    8. Short hairpin RNA-mediated knockdown of RhoGDI2 induces the invasion and migration of lung cancer due to cross-talk with the PI3K/Akt pathway and MMP-9. PMID: 25266803
    9. RhoGDI2 overexpression is associated with tumor growth, metastasis, and chemoresistance in gastric cancer. PMID: 24721928
    10. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma. PMID: 24788627
    11. RhoGDI2 inhibits trophoblast cell migration, and this function may involve suppression of RAC1 activation. PMID: 24554735
    12. 14-3-3sigma is a RhoGDI2-regulated gene that appears to be important for suppressing the chemoresistance of gastric cancer cells. PMID: 24185104
    13. These results suggest that RhoGDIbeta has mitotic functions, including regulation of cytokinesis and bipolar spindle formation PMID: 23232495
    14. Rictor regulates cell migration by suppressing RhoGDI2. PMID: 22777355
    15. RhoGDI2 becomes rapidly phosphorylated at Ser31 in response to phorbol 12-myristate 13-acetate stimulation. Conventional type PKCalpha is responsible for this phosphorylation. PMID: 22469974
    16. Expression of ARHGDIB variants 6a, 6b, and 6c appears to be restricted to cancer cells and normal placental tissue, suggesting that these variants possess cancer-specific functions. PMID: 23206989
    17. The ARHGDIB is a lymphoid-specific intrinsic negative regulator of HIV-1 replication that acts by simultaneously inhibiting RhoA and Rac1 functions. PMID: 21936715
    18. Results suggest that D4-GDI may function as a biphasic regulator of breast cancer progression and metastasis. PMID: 22674302
    19. We delineate the mechanism by which RhoGDI2 promotes gastric cancer cell invasion and chemoresistance. In total, 47 differential protein spots were identified; 33 were upregulated, and 14 were downregulated by RhoGDI2 overexpression. PMID: 22364609
    20. RhoGDI2 suppresses lung metastasis in mouse models by reducing the expression of isoforms V1 and V3 of the proteoglycan versican. RhoGDI2 suppressed metastasis by altering inflammation in the tumor microenvironment. PMID: 22406535
    21. Overexpression of RhoGDI2 correlates with tumor progression in colorectal carcinoma. PMID: 21861235
    22. activation of the Src family members and downstream signalling proteins are associated with a good prognosis in transitional cell carcinoma of the bladder, and activated Src has a positive relationship with RhoGD12. PMID: 22353809
    23. PLCgamma plays a key role in RhoGDI2-mediated cisplatin resistance and cell invasion in gastric cancer cells. PMID: 21986528
    24. identification of LyGDI as a binding partner of SHIP, associating inducibly with the SHIP/Grb2/Shc complex PMID: 21695085
    25. This study has revealed that Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and the HSP70/90 organizing protein have a critical role to play in resistance to cyclin-depedent kinases inhibitor. PMID: 21067243
    26. RhoGDI2 is likely to be involved in lung tumor malignancy and metastasis. PMID: 20596634
    27. High LyGDI serum levels are associated with ovarian cancer. PMID: 20375790
    28. RhoGDI2 is associated with c-Src in bladder tumors, where the expression of both is diminished as a function of stage. c-Src binds to and phosphorylates RhoGDI2 resulting in enhanced metastasis suppressive potency. Review. PMID: 20013033
    29. These data suggest that D4-GDI of Rho family GTPase may be regulated during apoptosis through the caspase-3 mediated cleavage of the GDI protein. PMID: 11989976
    30. Results demonstrate that modification of Rho guanine nucleotide dissociation inhibitor (GDI) 2 during apoptosis is often accompanied by their relocalisation between cellular compartments [Rho GDI 2 ] PMID: 12203895
    31. the interaction of Vav1 and Ly-GDI creates a fine tuning mechanism for the regulation of intracellular signaling pathways leading to NFAT stimulation PMID: 12386169
    32. RhoGDI2 has a role in progression of bladder cancer PMID: 15173088
    33. RhoGDI2 may be implicated in the progress of malignancy. PMID: 17487395
    34. One gene identified by microarray gene expression analysis, RhoGDI2, was tested and confirmed to be metastasis supressor gene; results from cells expressing RhoG-two molecular effectors of RhoGDI2 signaling were identified: endothelin-1 and Neuromedin U. PMID: 17826660
    35. Rho-GDI beta has two roles: one that suppresses tumor progression by inhibiting migration and the other that stimulates it by enhancing Cox-2 expression PMID: 18006811
    36. D4-GDI with two mutations (V68L & V69A) inhibited GDP dissociation from Rho in a dominant negative manner. It accelerates invasion via regulation of cytoskeletal machinery. PMID: 18037226
    37. Transgenic mice with T cell-specific expression display altered cellular immunity against cytozoic pathogens PMID: 18689726
    38. Overexpression of D4-GDI is associated with breast cancer. PMID: 19269969
    39. RhoGDI2 metastasis inhibition works through Rho GTPases but via a mechanism distinct from inhibition of membrane association. PMID: 19276387
    40. phosphorylation by Src enhances RhoGDI2 metastasis suppression and loss of Src relieves metastasis suppression in tumor cells that maintain RhoGDI2 expression. PMID: 19321744
    41. RhoGDI2 is involved in gastric tumor growth and metastasis, and that RhoGDI2 may be a useful marker for tumor progression of human gastric cancer. PMID: 19351766
    42. Results show that the established nerve invasion model and the consensus signature of perineural invasion could be instrumental in the identification of novel therapeutic targets of pancreatic cancer as exemplified by KIF14 and ARHGDIbeta. PMID: 19509238

    显示更多

    收起更多

  • 亚细胞定位：
    Cytoplasm, cytosol.
  • 蛋白家族：
    Rho GDI family
  • 组织特异性：
    Detected in bone marrow, thymus and spleen.
  • 数据库链接：

    HGNC: 679

    OMIM: 602843

    KEGG: hsa:397

    STRING: 9606.ENSP00000228945

    UniGene: Hs.504877